$0.00
+0.00 (+0.00%)
Open$0.00
Previous Close$0.00
Day High$0.00
Day Low$0.00
52W High$31,363.20
52W Low—
Volume—
Avg Volume15.69M
Market Cap2.64M
P/E Ratio—
EPS$-205,055.95
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+482,042.9% upside
Current
$0.00
$0.00
Target
$13.50
$13.50
$9.80
$13.50 avg
$19.20
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 11.18B | 10.47B | 180.5K |
| Net Income | -2,873,510,358,333 | -2,421,497,492,977 | -19,611 |
| Profit Margin | -25,708.3% | -24,422.8% | -10.9% |
| EBITDA | -2,290,571,274,425 | -2,037,493,174,816 | -25,362 |
| Free Cash Flow | — | — | -13,693 |
| Rev Growth | +6.8% | +6.8% | +10.1% |
| Debt/Equity | 0.65 | 0.65 | 0.93 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |